课题基金 / 基金详情

SAFETY OF ORAL IMIQUIMOD ADMINISTRATION IN CHRONIC HEPATITIS C PATIENTS

SAFETY OF ORAL IMIQUIMOD ADMINISTRATION IN CHRONIC HEPATITIS C PATIENTS
慢性丙型肝炎患者口服咪喹莫特的安全性
批准号：
5220277
负责人：
KENT G BENNER
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5220277
关键词：
antiviral agents blood chemistry clinical research clinical trial phase I drug screening /evaluation hepatitis C human subject human therapy evaluation immunotherapy interferon inducers oral administration pharmacokinetics urinalysis

项目摘要

项目成果

KENT G BENNER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This phase I study is designed to determine the safety and tolerance and, as secondary objectives, pharmacokinetics, immunomodulatory effect and antiviral effect of the oral interferon inducer Imiquimod in patients with chronic hepatitis C. This 6 month treatment trial will include 2 30 hr. CRC admissions for monitoring, and blood and urine collections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
URSODEOXYCHOLATE-METHOTREXATE FOR TREATMENT OF PRIMARY BILIARY CIRRHOSIS
Ursodeoxycholate-Methotrexate for Treatment of Primary Biliary Cirrhosis
NORTH AMERICAN STUDY OF TREATMENT FOR REFRACTORY ASCITES (NASTRA)
Study of sandostatin LAR in patients with cirrhosis
海外基金